ContractPlacement Agency Agreement • June 6th, 2025 • Cibus, Inc. • Agricultural chemicals • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and Cibus, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company on a “reasonable best efforts” basis in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares (the “Shares”) of Class A common stock, par value $0.0001 per share (“Common Stock”) and (ii) pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants” and, together with the Shares, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities purchase agreement to be ent
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 8th, 2025 • Theriva Biologics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 9th, 2025 • Immunic, Inc. • Pharmaceutical preparations • New York
ContractPlacement Agency Agreement • March 25th, 2025 • GeoVax Labs, Inc. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and GeoVax Labs, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded common stock purchase warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”), and (iii) common stock purchase warrants to purchase shares of Common Stock (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company a
ContractPlacement Agency Agreement • January 30th, 2025 • Wearable Devices Ltd. • Computer communications equipment • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Wearable Devices Ltd., a company organized under the laws of Israel (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best-efforts” basis, in connection with the proposed placement (the “Placement”) of the following registered securities: (i) ordinary shares (the “Shares”) of the Company, no par value per share (the “Ordinary Shares”), (ii) warrants to purchase Ordinary Shares (the “Warrants”) and (iii) pre-funded warrants to purchase Ordinary Shares (the “Pre-Funded Warrants” and together with the Ordinary Shares and Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, wit
ContractPlacement Agency Agreement • January 22nd, 2025 • Cibus, Inc. • Agricultural chemicals • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and Cibus, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares (the “Shares”) of Class A common stock, par value $0.0001 per share (“Common Stock”); (ii) pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”); and (iii) warrants to purchase Common Stock (the “Common Warrants” and together with the Pre-Funded Warrants and the Shares, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connecti
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 21st, 2025 • Theriva Biologics, Inc. • Pharmaceutical preparations • New York
ContractPlacement Agency Agreement • January 6th, 2025 • Wearable Devices Ltd. • Computer communications equipment • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Wearable Devices Ltd., a company organized under the laws of Israel (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best-efforts” basis, in connection with the proposed placement (the “Placement”) of the following registered securities: (i) ordinary shares (the “Shares”) of the Company, no par value per share (the “Ordinary Shares”), (ii) warrants to purchase Ordinary Shares (the “Warrants”) and (iii) pre-funded warrants to purchase Ordinary Shares (the “Pre-Funded Warrants” and together with the Ordinary Shares and Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, wit
ContractPlacement Agency Agreement • December 27th, 2024 • AMERICAN BATTERY TECHNOLOGY Co • Mining & quarrying of nonmetallic minerals (no fuels) • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and American Battery Technology Company, a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with th
ContractPlacement Agency Agreement • December 23rd, 2024 • AMERICAN BATTERY TECHNOLOGY Co • Mining & quarrying of nonmetallic minerals (no fuels) • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and American Battery Technology Company, a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with th
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 10th, 2024 • Theriva Biologics, Inc. • Pharmaceutical preparations • New York
ContractPlacement Agency Agreement • November 27th, 2024 • Wearable Devices Ltd. • Computer communications equipment • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Wearable Devices Ltd., a company organized under the laws of Israel (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best-efforts” basis, in connection with the proposed placement (the “Placement”) of (i) ordinary shares (the “Shares”) of the Company, no par value per share (the “Ordinary Shares”), (ii) warrants to purchase Ordinary Shares (the “Warrants”) and (iii) pre-funded warrants to purchase Ordinary Shares (the “Pre-Funded Warrants” and together with the Ordinary Shares and Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The terms of the Placement shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”), and nothing herein constit
Placement Agency AgreementPlacement Agency Agreement • October 24th, 2024 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 30th, 2024 • Theriva Biologics, Inc. • Pharmaceutical preparations • New York
ContractPlacement Agency Agreement • September 16th, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and INmune Bio Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”) and (ii) warrants to purchase Common Stock (the “Common Warrants”). The Common Stock and Common Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities purchase agreement (the “Purchase Agreement”), shall be collectively referred to herein as the “Tra
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 10th, 2024 • Theriva Biologics, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • September 9th, 2024 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • August 22nd, 2024 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
ContractPlacement Agency Agreement • June 13th, 2024 • Cibus, Inc. • Agricultural chemicals • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and Cibus, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of Class A common stock, par value $0.0001 per share (“Common Stock”) and (ii) warrants to purchase Common Stock (the “Common Warrants”). The Common Stock and Common Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities purchase agreement (the “Purchase Agreement”), shall be collectively referred to herein as t
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 9th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 25th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
ContractPlacement Agency Agreement • April 5th, 2024 • Matinas BioPharma Holdings, Inc. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.0001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with th
ContractPlacement Agency Agreement • March 21st, 2024 • Spire Global, Inc. • Communications services, nec • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Spire Global, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”) and greenshoe warrants (the “Greenshoe Warrants”) to purchase shares of Common Stock. The Shares and Greenshoe Warrants shall be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-267413), which was declared effective by the U.S. Securities and Exchange Commission on September 26, 2022 (the “Registration Statement”). The Shares and Greenshoe Warrants actually placed by the Placement Agent are referred to herein as the “Placement
ContractPlacement Agency Agreement • March 15th, 2024 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 9th, 2024 • Phunware, Inc. • Services-computer processing & data preparation • New York
ContractPlacement Agency Agreement • January 8th, 2024 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 11th, 2023 • Motus GI Holdings, Inc. • Surgical & medical instruments & apparatus • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 8th, 2023 • Foresight Autonomous Holdings Ltd. • Services-prepackaged software • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 2nd, 2023 • Vivos Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
ContractPlacement Agency Agreement • November 1st, 2023 • Zivo Bioscience, Inc. • Biological products, (no disgnostic substances) • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Zivo Bioscience, Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of C
ContractPlacement Agency Agreement • August 15th, 2023 • 180 Life Sciences Corp. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and 180 Life Sciences Corp., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.0001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 7th, 2023 • Athersys, Inc / New • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • July 26th, 2023 • Athersys, Inc / New • Pharmaceutical preparations • New York
Re: Placement Agency AgreementPlacement Agency Agreement • February 9th, 2023 • Digital Ally, Inc. • Radio & tv broadcasting & communications equipment • New York
This placement agency agreement (this “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Digital Ally, Inc., a company incorporated under the laws of the State of Nevada (the “Company”), that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of (a) [●] units (the “Units”), each Unit consisting of (i) one share (each, a “Share” and, collectively, the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) one warrant (each, a “Warrant” and, collectively, the “Warrants”) to purchase a share of Common Stock of the Company (each. a “Warrant Share” and. collectively, the “Warrant Shares”) and (b) [●] pre-funded units (the “Pre-Funded Units”), each Pre-Funded Unit consisting of (i) one pre-funded warrant (each, a “Pre-Funded Warrant” and, collectively, the
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 1st, 2021 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York